Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies

[1] Quintas-Cardama A(2018)CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma Oncotarget 9 29843-29844

[2] Quintas-Cardama A(2018)CAR T-cell therapy in large B-cell lymphoma N Engl J Med 378 1065-1537

[3] Wen H(2019)Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice Ann Transl Med 7 735-68

[4] Weist MR(2018)PET of adoptively transferred chimeric antigen receptor T cells with (89)Zr-Oxine J Nucl Med 59 1531-3068

[5] Ying Z(2019)Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin's lymphoma Mol Ther Oncolytics 15 60-638

[6] Cheson BD(2014)Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification J Clin Oncol 32 3059-953

[7] Lee DW(2019)ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells Biol Blood Marrow Transplant 25 625-113

[8] Ying Z(2019)A safe and potent anti-CD19 CAR T cell therapy Nat Med 25 947-1182

[9] Su T(2020)The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients Cryobiology 96 106-340

[10] Zheng PP(2018)Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts Drug Discov Today 23 1175-34

[1] Quintas-Cardama A(2018)CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma Oncotarget 9 29843-29844

[2] Quintas-Cardama A(2018)CAR T-cell therapy in large B-cell lymphoma N Engl J Med 378 1065-1537

[3] Wen H(2019)Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice Ann Transl Med 7 735-68

[4] Weist MR(2018)PET of adoptively transferred chimeric antigen receptor T cells with (89)Zr-Oxine J Nucl Med 59 1531-3068

[5] Ying Z(2019)Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin's lymphoma Mol Ther Oncolytics 15 60-638

[6] Cheson BD(2014)Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification J Clin Oncol 32 3059-953

[7] Lee DW(2019)ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells Biol Blood Marrow Transplant 25 625-113

[8] Ying Z(2019)A safe and potent anti-CD19 CAR T cell therapy Nat Med 25 947-1182

[9] Su T(2020)The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients Cryobiology 96 106-340

[10] Zheng PP(2018)Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts Drug Discov Today 23 1175-34